Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study

Abstract Background: Despite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating disorder (ED) psychopathology, its efficacy and tolerability, and its acceptability and adherence rate are unclear. Methods: We assessed the feasibility of a future definitive trial on olanzapine in young people with AN in an